Compare Crispr Therapeutics AG (CRSP) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard Total World Stock Index Fund ETF — how do they compare? Crispr Therapeutics AG trades at $51 (market cap $4.88B), while Vanguard Total World Stock Index Fund ETF trades at $159.69 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 20.8× Crispr Therapeutics AG's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| CRSP | VT | |
|---|---|---|
Market Cap | $4.88B | $101.70B |
Volume | 2,861,747 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $74.92 | $162.39 |
52-Week Low | $44.34 | $134.19 |
Typical Hold Time | 77 Days | 53 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Vanguard Total World Stock ETF (VT) trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains strong global diversification with over 9,700 holdings across developed and emerging markets. Recent news highlights VT's competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF, with analysts noting its comprehensive exposure and long-term performance advantages.
VT offers investors broad global equity exposure with low costs, though its expense ratio of 0.06% faces pressure from cheaper alternatives. The ETF's performance remains tied to global economic conditions, with risks including trade policy uncertainty and currency fluctuations. Analyst sentiment is generally positive for long-term diversification strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
